Drugs / LT3001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04809818 | Mar → Aug 2021 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05686642 | Apr 2023 → Dec 2026 expected | ischemic stroke | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05403866 | Aug 2022 → May 2025 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05198323 | Aug 2022 → Dec 2026 expected | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LT3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05198323 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT04809818 ↗ |